READ: Featured Drug Insights: February 2025 - Prime Therapeutics
READ: Featured Drug Insights: February 2025
Your source for all Prime Therapeutics' February 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for February 2025 will keep you informed on what’s trending now.
Released Feb. 28, 2025
Clinical Highlights: February 2025
An overview of clinical insights’ trending topics and timely drug information highlights, this month provides an update on the U.S. FDA's recent update on the shortages of Novo Nordisk’s semaglutide products (Ozempic, Wegovy) shortages and more.
A review of newly approved specialty drugs, recent drug launches and new indications in the last month, this month includes treosulfan (Grafapex), mirdametinib (Gomekli), suzetrigine (Journavx) and more.
Released Feb. 26, 2025
The second installment of this newly launched quarterly publication provides a view of the GLP-1 pipeline and anticipated indications. See what's coming in the GLP-1 pipeline.
Released Feb. 18, 2025
Featuring commentary by Simone Ndujiuba on developments in the oncology space, this installment features a look at the learnings and impact generated from artificial intelligence (AI) systems.
Released Feb. 14, 2025
FDA Decisions Expected for March 2025
A breakdown of FDA decisions expected of new drugs expected to hit the market. This edition covers ataluren (Translarna), condoliase, revakinagene taroretcel (NT-501) and more.
Released Feb. 13, 2025
Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features Macular telangiectasia (MacTel) type 2.
Released Feb. 7, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are prademagene zamikeracel / (Abeona) and rebisufligene etisparvovec / (Ultragenyx).
All brand names are property of their respective owners.